Clinical Trial Update: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Osimertinib in EGFR-mutant non-small cell lung cancer with brain or leptomeningeal metastases has completed. The study enrolled patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Leptomeningeal Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)

Snippet

Sponsor: Intergroupe Francophone de Cancerologie Thoracique | Conditions: Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis | Phase 2 | Status: COMPLETED